Shandong Kexing Bioproducts Co.,Ltd

Shandong Kexing Bioproducts integrates R&D, manufacturing and sales of biopharmaceuticals, with its production site offering Recombinant Human Erythropoietin Injection (EPO), Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rh-G-CSF, Filgrastim), and Combined Clostridium Butyricum and Bifidobacterium Powder for clinical and commercial use. The company develops recombinant genetic biological drugs and micro-ecological preparations serving clinical treatment needs for kidney diseases, tumors and gastrointestinal diseases, becoming a leading player in China's biopharmaceutical industry after more than 20 years of development, notably as China's No. 1 producer of CHO-cell-based Recombinant Human Erythropoietin Injection, with its EPSINO product being the first EPO product launched in the Chinese market and the only EPO product free of human albumin in China, alongside a first-class G-CSF product and a non-toxic bacteria combination product.